Journal
PLOS ONE
Volume 10, Issue 10, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0140576
Keywords
-
Categories
Funding
- Aarne Koskelo Foundation
- Helsinki University Central Hospital
- Tampere University Hospital special government funds (EVO)
- Finnish Foundation for Cardiovascular research
- Academy of Finland
- Finnish Funding Agency for Technology and Innovation
- Integrative Life Science Doctoral Program of the University of Helsinki
- Medical Research Fund of Tampere University Hospital
- Pirkanmaa Regional Fund of the Finnish Cultural Foundation
- Sigrid Juselius Foundation
- Academy of Finland [139635]
- Finnish Foundation for Cardiovascular Diseases
- Finnish Academy [129388, 269517]
- EU [313010, 305280, 261433]
- Yrjo Jahnsson Foundation
- Juho Vainio Foundation
- Aarne Koskelo Foundation
- Helsinki University Central Hospital
- Tampere University Hospital special government funds (EVO)
- Finnish Foundation for Cardiovascular research
- Academy of Finland
- Finnish Funding Agency for Technology and Innovation
- Integrative Life Science Doctoral Program of the University of Helsinki
- Medical Research Fund of Tampere University Hospital
- Pirkanmaa Regional Fund of the Finnish Cultural Foundation
- Sigrid Juselius Foundation
- Academy of Finland [139635]
- Finnish Foundation for Cardiovascular Diseases
- Finnish Academy [129388, 269517]
- EU [313010, 305280, 261433]
- Yrjo Jahnsson Foundation
- Juho Vainio Foundation
- Academy of Finland (AKA) [129388, 129388, 139635] Funding Source: Academy of Finland (AKA)
Ask authors/readers for more resources
Myocardial infarction (MI) is divided into either ST elevation MI (STEMI) or non-ST elevation MI (NSTEMI), differing in a number of clinical characteristics. We sought to identify genetic variants conferring risk to NSTEMI or STEMI by conducting a genome-wide association study (GWAS) of MI stratified into NSTEMI and STEMI in a consecutive sample of 1,579 acute MI cases with 1,576 controls. Subsequently, we followed the results in an independent population-based sample of 562 cases and 566 controls, a partially independent prospective cohort (N = 16,627 with 163 incident NSTEMI cases), and examined the effect of disease-associated variants on gene expression in 513 healthy participants. Genetic variants on chromosome 1p13.3 near the damage-regulated autophagy modulator 2 gene DRAM2 associated with NSTEMI (rs656843; odds ratio 1.57, P = 3.11 x 10(-10)) in the case-control analysis with a consistent but not statistically significant effect in the prospective cohort (rs656843; hazard ratio 1.13, P = 0.43). These variants were not associated with STEMI (rs656843; odds ratio, 1.11, P = 0.20; hazard ratio 0.97, P = 0.87), appearing to have a pronounced effect on NSTEMI risk. A majority of the variants at 1p13.3 associated with NSTEMI were also associated with the expression level of DRAM2 in blood leukocytes of healthy controls (top-ranked variant rs325927, P = 1.50 x 10(-12)). The results suggest that genetic factors may in part influence whether coronary artery disease results in NSTEMI rather than STEMI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available